EGFR and neoplasm: Although none of these patients experienced an objective response, one with carcinoma of unknown primary and EGFR amplification (copy number 8.45) and treated with panitumumab showed tumor shrinkage in some of the metastatic lesions; however, treatment benefit for the remaining patients was limited.